Letter to the Editor
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 21, 2024; 30(39): 4308-4312
Published online Oct 21, 2024. doi: 10.3748/wjg.v30.i39.4308
Novel intervention for alcohol-associated liver disease
Fei-Qiong Gao, Jia-Qi Zhu, Xu-Dong Feng
Fei-Qiong Gao, Department of Endocrinology, The Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou 310003, Zhejiang Province, China
Jia-Qi Zhu, Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, Zhejiang Province, China
Xu-Dong Feng, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, The Affiliated Lihuili Hospital of Ningbo University, Ningbo 315000, Zhejiang Province, China
Author contributions: Gao FQ and Feng XD conceived the idea of the manuscript; Gao FQ wrote the draft; Zhu JQ reviewed the literature; Feng XD revised the manuscript; all authors approved the final manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu-Dong Feng, MD, PhD, Doctor, Department of Clinical Laboratory, Ningbo Medical Center Lihuili Hospital, The Affiliated Lihuili Hospital of Ningbo University, No. 57 Xingning Road, Ningbo 315000, Zhejiang Province, China. xdfeng@zju.edu.cn
Received: July 20, 2024
Revised: August 27, 2024
Accepted: September 19, 2024
Published online: October 21, 2024
Processing time: 84 Days and 0.6 Hours
Core Tip

Core Tip: Alcohol-associated liver disease (ALD) remains a significant global health challenge. Peroxisome proliferator-activated receptors α and δ (PPARα/δ) play a crucial role in the pathogenesis of ALD. Elafibranor, a dual PPARα/δ activator, shows promise as a potential therapeutic agent for ALD.